Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 8516 publications.

Brogan A. Advancing accuracy and transparency in health economic evaluation. Presentation to be given at the ISPOR 2025; May 16, 2025. Montreal, Canada.

Bozzi LM, Johnson R, Heidenreich S, Poulos C. Alternative recruitment options for patient preference studies: thinking outside the market research panel box. Presentation to be given at the ISPOR 2025; May 16, 2025. Montréal, Canada.

Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster to be given at the ISPOR 2025; May 16, 2025. Montréal, Canada.

La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Copley-Merriman K, Doward L, Hawe E, Cope S. Clinical trial design, beyond the regulatory. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Brogan A, Zhang K. From data to dialogue: mastering conversations to amplify HEOR impact and influence. Presentation to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Loria-Rebolledo L, Watson V, Mohan D, Vass CM, Antunes M, Burns D, Ryan M. Over 30 years of discrete choice experiment studies in health economics: systematic review of current practice and reflections on evolving practice. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Marcano Belisario J, Lunan M, Hawe E, Farrelly G. Evaluation of machine learning assisted title and abstract screening in 5 clinical systematic literature reviews. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Sauchelli S, Chicklis EK, Carty MK, Gnanasakthy A. Use of diaries to capture patient-reported outcomes in FDA new drug approvals (2019-2023). Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pizzi L, Earnshaw S, Blanchette C, Thompson D. Climbing the HEOR career ladder: strategies for success in an era of change. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Dellon ES, Goodwin B, Liu E, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED. Eosinophilic esophagitis-related healthcare resource utilization and associated costs for payers and patients: a retrospective cohort study of US health insurance claims data. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Ronquest N, Zhang Y, Mladsi D. Assessing the impact of the United States (US) Inflation Reduction Act (IRA) regulations on investment incentives for orphan disease drug development. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The potential public health and economic benefit of an mRNA-based RSV vaccine, mRNA-1345, among high-risk adults aged 18-59 years in the US: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Gnanasakthy A, Crawford R, Qin S, Doward L, Rockwood NJ. Advanced patient-reported outcomes. Mastering Patient-Reported Outcomes (PRO) in Drug Development. Presentation to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada. Previously presented at the ISPOR Europe 2024.

Yano Y, Okami S, Kanegae H, Oberprieler NG, Johannes C, Yamashita S, Yoshikawa-Ryan K, Kovesdy CP, Vizcaya D, Kashihara N. Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-a hospital-based cohort study in Japan. Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16394

Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination: primary care provider knowledge, attitudes, and practices. Hum Vaccin Immunother. 2025 Apr 18;21(1):2488093. doi: 10.1080/21645515.2025.2488093

Tamhankar MA, Raza S, Brutsaert E, Urdaniz E, Vainilovich Y, Heyes A, Gildea L, Sales-Sanz M. The burden of illness in thyroid eye disease: current state of the evidence. Front Ophthalmol. 2025 Apr 16;5. doi: 10.3389/fopht.2025.1565762

Leber B, Ruiz MT, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh AC. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer. 2025 Apr 15;131(8):e35845. doi: 10.1002/cncr.35845

Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8

La EM, Sweeney C, Davenport E, Bunniran S. Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults. Vaccine. 2025 Apr 8;54:127057. doi: 10.1016/j.vaccine.2025.127057

Abbatemarco J, Yu J, Kleman M, Myers K, Poulos C, Conway D. Patient preferences for treatment features in Neuromyelitis Optica Spectrum Disorder (NMOSD): results from a discrete choice experiment (DCE). Poster presented at the American Academy of Neurology 2025 Annual Meeting; April 5, 2025. San Diego, CA. [abstract] Neurology. 2025 Apr 8; 104(7_Suppl 1):7-8.013. doi: 10.1212/WNL.0000000000208724

Custer N, Lesko T, Reategui EP. What is data integrity and data quality? In: Richard M Siconolfi, Catherine Bens, Josepah A. Franchetti, Cheryl M. McCarthy, editors. Data integrity: the science, the regulations, the use. First ed. Charlottesville: VA. SQA Learning Foundation Educational Book; 2025.

Poulos C, Marcek T, Chintakayala P, Boeri M, Francis A, Langevin E, Petigara T, O'Connor J, Samant S. Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):543-50. doi: 10.1080/14737167.2025.2450352

Craig T, Baptist AP, Anderson J, Zaragoza-Urdaz RH, Burnette AF, Kelbel TE, Riedl MA, Vanegas A, Boyle K, Bartsch JL, Darden C, Brown TM, Schultz BG, Blair C, Sing K, Fox D, Juethner S. Hereditary angioedema: patient health care experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol. 2025 Apr;134(4):465-473.e. doi: 10.1016/j.anai.2025.01.007

Horn EK, La EM, Bektas M, Khan S, Gerber SI. Disparities in respiratory syncytial virus risk factors, diagnosis, and outcomes in adults by race, ethnicity, and other social determinants of health in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):459-71. doi: 10.1080/14737167.2024.2441867

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Skoldunger A, Raket LL, Stellick CB, Spackman E, Hlavka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Bruck C, Anderson R, Pemberton-Ross P, Urbich M, Jonsson L. IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease. Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006

Handels R, Herring WL, Grimm S, Skoldunger A, Winblad B, Wimo A, Jonsson L. New IPECAD open-source model framework for the health technology assessment of early Alzheimer's disease treatment: development and use cases. Value Health. 2025 Apr;28(4):511-8. doi: 10.1016/j.jval.2024.07.009

Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.

Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. Overall survival with palbociclib and aromatase inhibitor versus aromatase inhibitor alone in older patients with HR+/HER2− metastatic breast cancer. Cancer Med. 2025 Apr;14(7):e70719. doi: 10.1002/cam4.70719

McHugh N, Bomark D, Baker R, Watson V, Craig N, Donaldson C. Trading-off outcomes and policy characteristics of a universal basic income and a minimum income guarantee: evidence from an exploratory mixed-method preference-based study. Soc Sci Med. 2025 Apr;370:117855. doi: 10.1016/j.socscimed.2025.117855

Vickers AD. A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis. Value Health. 2025 Apr;28(4):591-8. doi: 10.1016/j.jval.2025.01.005

Garcia de Albeniz Martinez X. Validate study variables to reduce misclassification bias: recent tools and research needs. Presented at the ARS Toscana Webinar; March 27, 2025. Florence, Italy.

Paret K, Chaiyakunapruk N, Ronquest N, Pearson I. Introduction to best practices for country adaptations of economic models - virtual. Presented at the 2025 Virtual ISPOR Short Course Program; March 26, 2025. Previously presented at the 2024 Virtual ISPOR Short Course Program.

Wilson MR, Castaman G, Thomas W, Millar CM, Escolar G, Miesbach WA, McDade CL, Tomic R, Yan S. Cost-effectiveness of voncento prophylaxis versus on-demand treatment in von willebrand disease in the United Kingdom. Blood Adv. 2025 Mar 25;9(6):1312-9. doi: 10.1182/bloodadvances.2024014376

Jedynak P, Bustamante M, Rolland M, Mustieles V, Thomsen C, Sakhi AK, Sabaredzovic A, Foraster M, Gascon M, Gomez-Roig MD, Llurba E, Rivas I, Ouellet-Morin I, Bayat S, Lyon-Caen S, Pozo OJ, Vrijheid M, Sunyer J, Slama R, Dadvand P, Philippat C. Prenatal exposure to synthetic phenols assessed in multiple urine samples and dysregulation of steroid hormone homeostasis in two European cohorts. Environ Health Perspect. 2025 Mar 21. doi: 10.1289/EHP15117

Zubizarreta-Arruti U, Bosch R, Soler Artigas M, Cabana-Dominguez J, Llonga N, Carabi-Gassol P, Macias-Chimborazo V, Vilar-Ribo L, Ramos-Quiroga JA, Pagerols M, Prat R, Rivas C, Pagespetit E, Puigbo J, Espanol-Martin G, Raimbault B, Valentin A, Sunyer J, Foraster M, Gascon M, Casas M, Ribases M, Alemany S. Associations between air pollution and surrounding greenness with internalizing and externalizing behaviors among schoolchildren. Child Adolesc Ment Health. 2025 Mar 21. doi: 10.1111/camh.12772

Pladevall-Vila M, Ziemiecki R, Johannes CB, Khan AM, Mines D, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, Garcia-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Bernal CR, Cabaninas CR, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Beest FJAP, Yamashita S, Yano Y, Layton JB, Vizcaya D, Oberprieler NG. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: a multinational cohort study. Diabetes Ther. 2025 Mar 19. doi: 10.1007/s13300-025-01717-8

Vila Guilera J, Abellan A, Garcia de Albeniz X, Houghton K. External control arm studies in marketing authorisation applications submitted to the European Medicines Agency: a review of study design features and methods. Presented at the Drug Information Association (DIA) Europe 2025; March 18, 2025. Basel, Switzerland.